-
Amgen Inc. v. Zydus Pharmaceuticals (USA) Inc. et al DC CAFC
- 1:17-cv-00183
- D. Del.
- Filed: 02/21/2017
- Closed: 09/14/2020
- Latest Docket Entry: 09/14/2020
- Judge: Mitchell S. Goldberg
- PACER
1
Plaintiff
2
Defendants
1
Accused
Product
1
Patent-in-Suit
1,302
Days in
Litigation
-
Amgen Inc. v. Zydus Pharmaceuticals (USA) Inc. et al DC CAFC
- 1:17-cv-00183
- D. Del.
- Filed: 02/21/2017
- Closed: 09/14/2020
- Latest Docket Entry: 09/14/2020
- Judge: Mitchell S. Goldberg
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition comprising: (a) from about 10% to about 40% by weight of cinacalcet HCl in an amount of from about 20 mg to about 100 mg; (b) from about 45% to about 85% by weight of a diluent selected from the group consisting of
view more
|
Valid
Entry 11 |
2 |
The composition according to claim 1, further comprising at least one excipient selected from the group consisting of lubricants and clear and color coating materials.
|
Valid
Entry 11 |
3 |
The composition according to claim 1, further comprising from about 1% to about 6% by weight of at least one coating material selected from the group consisting of clear and color coating materials wherein the percentage by weight is relative to the
view more
|
Valid
Entry 11 |
4 |
The composition according to claim 1, further comprising from about 0.05% to about 5% of at least one additive selected from the group consisting of glidants, lubricants and adherents, wherein the percentage by weight is relative to the total weight
view more
|
Valid
Entry 11 |
6 |
The composition according to claim 1, wherein the at least one disintegrant is crospovidone.
|
Valid
Entry 11 |
8 |
The composition according to claim 1, wherein the cinacalcet HCl is in a form selected from the group consisting of amorphous powders, crystalline particles, and mixtures thereof.
|
Valid
Entry 11 |
9 |
The composition according to claim 8 wherein the particle D<sub>50 </sub>of the cinacalcet HCl particles is less than or equal to about 50 μm.
|
Valid
Entry 11 |
15 |
The composition according to claim 1 wherein the composition comprises granules.
|
Valid
Entry 11 |
16 |
The composition according to claim 1 further comprising from about 0.05% to about 1.5% by weight of colloidal silicon dioxide relative to the total weight of the composition.
|
Valid
Entry 11 |
17 |
The composition according to claim 1 further comprising from about 0.05% to about 1.5% by weight of magnesium stearate relative to the total weight of the composition.
|
Valid
Entry 11 |
19 |
The composition according to claim 1, wherein the diluent is microcrystalline cellulose or starch.
|
Valid
Entry 11 |
-
Infringement
Cadila Healthcare Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Cinacalet HCI Tablets 30 mgCinacalet HCI Tablets 60mgCinacalet HCI Tablets 90mg | US 9,375,405 B2 |
1, 2, 3, 4, 6, 8, 9, 15, 16, 17, 19
|
No infringement
Entry 11
|
Zydus Pharmaceuticals (USA) Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Cinacalet HCI Tablets 30 mgCinacalet HCI Tablets 60mgCinacalet HCI Tablets 90mg | US 9,375,405 B2 |
1, 2, 3, 4, 6, 8, 9, 15, 16, 17, 19
|
No infringement
Entry 11
|